Morgan Stanley’s TScan Therapeutics TCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$175K Sell
173,643
-52,186
-23% -$55.8K ﹤0.01% 5926
2025
Q4
$226K Sell
225,829
-621,708
-73% -$900K ﹤0.01% 5886
2025
Q3
$1.54M Sell
847,537
-5,809
-0.7% -$10.3K ﹤0.01% 4931
2025
Q2
$1.24M Buy
853,346
+260,376
+44% +$376K ﹤0.01% 4994
2025
Q1
$818K Buy
592,970
+180,112
+44% +$390K ﹤0.01% 5100
2024
Q4
$1.26M Buy
412,858
+113,539
+38% +$515K ﹤0.01% 4972
2024
Q3
$1.49M Buy
299,319
+57,647
+24% +$348K ﹤0.01% 4816
2024
Q2
$1.41M Buy
241,672
+17,778
+8% +$140K ﹤0.01% 4777
2024
Q1
$1.78M Sell
223,894
-245,512
-52% -$1.54M ﹤0.01% 4660
2023
Q4
$2.74M Buy
469,406
+209,959
+81% +$961K ﹤0.01% 4757
2023
Q3
$664K Buy
259,447
+150,972
+139% +$352K ﹤0.01% 5026
2023
Q2
$271K Sell
108,475
-22,844
-17% -$61.3K ﹤0.01% 5510
2023
Q1
$276K Buy
131,319
+89,144
+211% +$212K ﹤0.01% 5557
2022
Q4
$65.4K Sell
42,175
-22,395
-35% -$54.9K ﹤0.01% 6170
2022
Q3
$197K Buy
64,570
+7,481
+13% +$24.5K ﹤0.01% 5733
2022
Q2
$180K Buy
57,089
+18,013
+46% +$49.3K ﹤0.01% 5956
2022
Q1
$110K Buy
39,076
+11,672
+43% +$50.5K ﹤0.01% 6251
2021
Q4
$123K Sell
27,404
-832
-3% -$6.01K ﹤0.01% 6317
2021
Q3
$235K Buy
+28,236
New +$262K ﹤0.01% 5908

Other funds holding TCRX